Home  |  Contact

UniProtKB/Swiss-Prot Q70SY1: Variant p.Val130Ile

Cyclic AMP-responsive element-binding protein 3-like protein 2
Gene: CREB3L2
Variant information

Variant position:  130
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LB/B
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Valine (V) to Isoleucine (I) at position 130 (V130I, p.Val130Ile).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Similar physico-chemical property. Both residues are medium size and hydrophobic.
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  3
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  130
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  520
The length of the canonical sequence.

Location on the sequence:   ESEKWYLSTDFPSTSIKTEP  V TDEPPPGLVPSVTLTITAIS
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         ESEKWYLSTDF----PSTSIKTE-PVTDEPPPGLVPSVTLTITAIS-

Mouse                         ESEKWYLSTEF----PSATIKTE-PITEEQPPGLVPSVTLT

Rat                           ESEKWYLSTEF----PSATIKTE-PITEEQPPGLVPSVTLT

Xenopus laevis                TGDDWCLNGELTATTPTTKIKVEIPLEETP--GLTPSVTLA

Zebrafish                     ESDEWPMEQE------DKGIKME-PLLCVP----LPALTLT

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 520 Cyclic AMP-responsive element-binding protein 3-like protein 2
Topological domain 1 – 379 Cytoplasmic


Literature citations

Fusion of the FUS and BBF2H7 genes in low grade fibromyxoid sarcoma.
Storlazzi C.T.; Mertens F.; Nascimento A.; Isaksson M.; Wejde J.; Brosjoe O.; Mandahl N.; Panagopoulos I.;
Hum. Mol. Genet. 12:2349-2358(2003)
Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1); VARIANTS THR-100 DEL AND ILE-130; TISSUE SPECIFICITY; CHROMOSOMAL TRANSLOCATION WITH FUS;

Human chromosome 7: DNA sequence and biology.
Scherer S.W.; Cheung J.; MacDonald J.R.; Osborne L.R.; Nakabayashi K.; Herbrick J.-A.; Carson A.R.; Parker-Katiraee L.; Skaug J.; Khaja R.; Zhang J.; Hudek A.K.; Li M.; Haddad M.; Duggan G.E.; Fernandez B.A.; Kanematsu E.; Gentles S.; Christopoulos C.C.; Choufani S.; Kwasnicka D.; Zheng X.H.; Lai Z.; Nusskern D.R.; Zhang Q.; Gu Z.; Lu F.; Zeesman S.; Nowaczyk M.J.; Teshima I.; Chitayat D.; Shuman C.; Weksberg R.; Zackai E.H.; Grebe T.A.; Cox S.R.; Kirkpatrick S.J.; Rahman N.; Friedman J.M.; Heng H.H.Q.; Pelicci P.G.; Lo-Coco F.; Belloni E.; Shaffer L.G.; Pober B.; Morton C.C.; Gusella J.F.; Bruns G.A.P.; Korf B.R.; Quade B.J.; Ligon A.H.; Ferguson H.; Higgins A.W.; Leach N.T.; Herrick S.R.; Lemyre E.; Farra C.G.; Kim H.-G.; Summers A.M.; Gripp K.W.; Roberts W.; Szatmari P.; Winsor E.J.T.; Grzeschik K.-H.; Teebi A.; Minassian B.A.; Kere J.; Armengol L.; Pujana M.A.; Estivill X.; Wilson M.D.; Koop B.F.; Tosi S.; Moore G.E.; Boright A.P.; Zlotorynski E.; Kerem B.; Kroisel P.M.; Petek E.; Oscier D.G.; Mould S.J.; Doehner H.; Doehner K.; Rommens J.M.; Vincent J.B.; Venter J.C.; Li P.W.; Mural R.J.; Adams M.D.; Tsui L.-C.;
Science 300:767-772(2003)
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]; VARIANTS THR-100 DEL AND ILE-130;

The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
The MGC Project Team;
Genome Res. 14:2121-2127(2004)
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3); VARIANTS THR-100 DEL AND ILE-130;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.